Adolfo Diaz Duque
Associate Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (12)
Cancer disparities among Latinos in the United States persist as a significant public health challenge, characterized by inequitable outcomes throughout the cancer continuum. Latinos experience elevated rates and poorer prognoses in certain cancers compared to other populations, driven by complex, multilevel interactions involving environmental exposures, genetic factors, cultural practices, and systemic inequalities. Recognizing the substantial heterogeneity among Latinos—including differences in national origin, immigration experiences, socioeconomic status, language, and race—is crucial, as oversimplification risks masking key disparities. To comprehensively understand these dynamics, the Task Force: Latino Researchers Against Cancer (TFLRAC) convened specialists in oncology, public health, and behavioral sciences to systematically examine the multiple influences contributing to these disparities. Findings highlight environmental hazards, genetic susceptibilities, cultural stigmas, and linguistic barriers as significant drivers. Systemic issues such as discrimination, colorism, inadequate healthcare coverage, workforce disparities, socioeconomic challenges, and underrepresentation in clinical trials further compound these inequities. Addressing these disparities requires a multifaceted strategy, including targeted research, culturally tailored interventions, and comprehensive policy reforms to improve healthcare access, workforce diversity, and clinical trial inclusion. Collaborative efforts across academia, healthcare systems, community organizations, governmental agencies, and industry partners are imperative to achieve equitable cancer outcomes among Latinos.
Year:
2025
Purpose: Glioblastoma represents the most common primary brain tumor. Although antiangiogenics are used in the recurrent setting, they do not prolong survival. Glioblastoma is known to upregulate fatty acid synthase (FASN) to facilitate lipid biosynthesis. TVB-2640, a FASN inhibitor, impairs this activity. Patients and Methods: We conducted a prospective, single-center, open-label, unblinded, phase II study of TVB-2640 plus bevacizumab in patients with recurrent high-grade astrocytoma. Patients were randomly assigned to TVB-2640 (100 mg/m 2 oral daily) plus bevacizumab (10 mg/kg i.v., D1 and D15) or bevacizumab monotherapy for cycle 1 only (28 days) for biomarker analysis. Thereafter, all patients received TVB-2640 plus bevacizumab until treatment-related toxicity or progressive disease (PD). The primary endpoint was progression-free survival (PFS). Results: A total of 25 patients were enrolled. The most frequently reported adverse events (AE) were palmar–plantar erythrodysesthesia, hypertension, mucositis, dry eye, fatigue, and skin infection. Most were grade 1 or 2 in intensity. The overall response rate (ORR) for TVB-2640 plus bevacizumab was 56% (complete response, 17%; partial response, 39%). PFS6 for TVB-2640 plus bevacizumab was 31.4%. This represented a statistically significant improvement in PFS6 over historical bevacizumab monotherapy (BELOB 16%; P = 0.008) and met the primary study endpoint. The observed OS6 was 68%, with survival not reaching significance by log-rank test ( P = 0.56). Conclusions: In this phase II study of relapsed high-grade astrocytoma, TVB-2640 was found to be a well-tolerated oral drug that could be safely combined with bevacizumab. The favorable safety profile and response signals support the initiation of a larger multicenter trial of TVB-2640 plus bevacizumab in astrocytoma.
Year:
2025
Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study aims to examine the influence of sociocultural, medical, stress-related, psychosocial, lifestyle, behavioral, and biological factors on symptom burden, health-related quality of life, and clinical outcomes among Hispanics/Latinos who have been previously treated for cancer. Avanzando Caminos is a prospective, cohort-based study of 3000 Hispanics/Latinos who completed primary cancer treatment within the past 5 years that is representative of the general Hispanic/Latino population in the United States. Participants will complete self-report measures at baseline (time [T] 1), 6 months (T2), 1 year (T3), 2 years (T4), 3 years (T5), 4 years (T6), and 5 years (T7). Blood samples drawn for assessment of leukocyte gene expression, cardiometabolic markers, and genetic admixture will be collected at baseline (T1), 1 year (T3), 3 years (T5), and 5 years (T7). Medical and cancer characteristics and clinical outcomes will be extracted from the electronic medical record and/or state cancer registry at each time point. Data analysis will include general latent variable modeling and latent growth modeling. Avanzando Caminos will fill critical gaps in knowledge in order to guide future secondary and tertiary prevention efforts to mitigate cancer disparities and optimize health-related quality of life among Hispanic/Latino cancer survivors.
Year:
2024
Background: Diffuse large B-cell lymphoma (DLBCL) is a common and often fatal malignancy. The standard-of-care immunochemotherapy, R-CHOP, cures only about 60% of DLBCL patients. Improving this cure rate will likely require the effective translation of basic biology knowledge into clinical activities. We previously identified the cyclic-AMP/phosphodiesterase 4 (PDE4) axis as an important modulator of lymphomagenic processes. We also showed that the FDA-approved PDE4 inhibitor roflumilast can suppress B-cell receptor (BCR) signals, phosphoinositide 3-kinase (PI3K) activity and angiogenesis. These data suggested that combining roflumilast with R-CHOP may be beneficial in DLBCL. Methods: We conducted a single-center, single-arm, open-label, phase 1 study of roflumilast in combination with the standard of care, R-CHOP (Ro+R-CHOP), in pathologically proven, treatment-naïve, high-risk DLBCL patients. Results: Ro+R-CHOP was safe, and at a median follow-up time of 44 months, 70% of patients were alive and disease free (median OS not reached, PFS 44% (95% CI, 21–92). In this pilot series, we found that the addition of roflumilast suppressed PI3K activity in peripheral blood mononuclear cells, and VEGF-A secretion in the urine. We also encountered preliminary evidence to suggest that the Ro+R-CHOP combination may be particularly beneficial to patients diagnosed with high-risk genetic subtypes of DLBCL, namely MCD and A53. Conclusions: These initial findings suggest that roflumilast may be an alternative agent able to inhibit BCR/PI3K activity and angiogenesis in DLBCL, and that the testing of Ro+R-CHOP in a larger series of genetically characterized tumors is warranted. This study was registered at ClinicalTrials.gov, number NCT03458546.
Year:
2024
Background: Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, has had improved progression free survival (PFS) in the first-line setting; however, prognosis remains poor for those with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL). Further analysis of SCHOLAR-1 demonstrated that those with refractory DLBCL, defined as progressive disease (PD) or stable disease (SD) as best response after four cycles of first-line therapy or following salvage therapy for relapsed disease or relapse ≤12 months following autologous stem cell transplantation had a median overall survival (OS) of 6.3 months (Blood PMID 28774879). Furthermore, at two years, 20% of patients were alive. This analysis emphasized the need for effective treatments in the setting of RR DLBCL. Since 2017, multiple phase 2 trials have led to accelerated FDA approvals including the L-MIND and LOTIS-2 studies that evaluated tafasitamab plus lenalidomide (TL) and loncastuximab tesirine (LT), respectively. However, Hispanics (HI) were an underrepresented group in these clinical trials, which is of concern due to healthcare disparities. L-MIND reported race (88.9% white, 2.5% Asian, and 8.6% unknown or not reported), but not ethnicity (Lancet Oncol PMID 32511983). Moreover, only 9.0% of patients identified as HI in the LOTUS-2 trial (Lancet Oncol PMID 33989558). This retrospective study was conducted at the only National Cancer Institute (NCI) Designated Cancer Center of South Texas, and aimed to highlight the demographics, treatment patterns, and real-world outcomes in a predominately HI population with RR DLBCL with TL, LT, or both. Methods: Baseline and treatment characteristics were collected and analyzed amongst patients with RR DLBCL treated with TL and/or LT at the University of Texas Health San Antonio MD Anderson Cancer Center from October 26, 2020 to July 1, 2024. Kaplan-Meier method was used to estimate PFS and OS in patients treated with TL and/or LT. Results: As of July 1, 2024, 22 patients with RR DLBCL were treated with TL, LT, or both. Of which, 77% identified as HI. Median age was 59 years old (range 24-81 years) and 59% were males. All patients were insured, including 64% with government sponsored insurance and the remaining with private insurance. Patients predominately presented with stage IV disease (59%) and International Prognostic Index score 2-3 (41%) at time of initial diagnosis. Of all patients, 45% had bulky disease. Germinal center B-cell like DLBCL accounted for 64% of all diagnoses. Of all patients, 32% received only TL and 46% received only LT; the remaining patients received TL with LT as a subsequent line of therapy. TL was given as a second line of therapy in 47% treated with TL; the remaining patients had two or more prior lines of therapy. All patients treated with LT had two or more prior lines of therapy. Refractory disease to the prior line of therapy was identified in 67% treated with TL and 67% treated with LT. In those treated with TL, 27% achieved complete response (CR), 7% had partial response (PR), 7% had SD, 33% had PD, and 27% died prior to restaging imaging. In all patients treated with LT, 50% achieved CR, 25% had PD, 17% were lost to follow, and 8% died prior to restaging imaging. Among those who received TL prior to LT, 60% achieved CR, 20% had PD, and 20% died prior to restaging imaging. PFS at 12 months and 24 months was 40% and 13%, respectively, in those treated with TL. Median PFS was 4.1 months. OS in those treated with TL at 12 months was 59% and at 24 months was 59%. Median OS was 40 months. PFS in patients treated with LT at 12 months was 17% and at 24 months was 0%. Median PFS was 7.0 months. OS in those treated with LT at 12 months and 24 months was 67% and 51%, respectively. Median OS was not determined due to small sample size. Among those treated with TL prior to LT, median PFS was 4.0 months and median OS was 4.9 months. Conclusion: Real-world outcomes with TL
Year:
2024
Year:
2024
Background: Primary effusion lymphoma (PEL) is a rare and aggressive non-Hodgkin lymphoma associated with HIV and human herpesvirus 8 (HHV-8). (Blood PMID: 8695812). Without treatment, patients typically survive only two to three months (Oncol Res Treat PMID: 28253516) Limited research has been conducted on PEL, particularly in minorities in the United States. Limited research, especially in minority populations (Blood PMID: 30154110), has prompted a nationwide study comparing demographics, clinical characteristics, treatment patterns, and survival outcomes between Hispanic (HI) and Non-Hispanic (NH) PEL patients. Methods: Data on PEL patients from the National Cancer Database (NCDB) between 2004 and 2019 were analyzed in the US. Demographics and treatment characteristics were compared across ethnic groups. Kaplan-Meier and Cox regression analyses were used to compare overall survival (OS) between HI and NH populations. Multivariate analysis and propensity score matching were conducted, adjusting for age, stage, co-morbidity score, insurance status, type of facility, and great circle distance. Results: Of 459 PEL patients, 18% were HI, and 79% were NH. Both groups had mostly male patients (87% vs. 86%). HI patients were younger at diagnosis (mean 49 years vs. 57 years, p=0.163). Diagnoses were mostly from 2014-2019, and the majority were white (87% vs. 69%). Government-sponsored insurance was more prevalent in both groups (62% vs. 66%). HI had a higher percentage of uninsured individuals (8% vs. 5% NH) (p-value=0.01). The median income bracket was over $46,000 for both cohorts, HI 34% and NH 37%. Advanced comorbidities were similar between HI 50% and NH 43% based on Charlson-Deyo Score. The survival probabilities at 2, 5, and 10 years for HI vs NH were (40% vs 40%), (34% vs 289%), and (34% vs 24%), respectively. The median survival time (MS) was 0.8 years for HI and 0.9 years for NH. There was no overall survival (OS) difference (p-value=0.51). On multivariate analysis, there were no independent variables associated with better or worse OS. The propensity-matched analysis showed no MS difference between HI and NH (0.80 vs 0.71 years). Conclusion: This hospital-based analysis confirmed low survival rates and revealed no statistical differences in MS or OS among HI and NH individuals with PEL. Interestingly, the disease was more prevalent in high-income subjects in both cohorts, despite HI individuals having lower insurance rates. A better understanding of intrinsic disease characteristics and biological variables can offer valuable insights into how to unveil potential targets of better and hopefully meaningful therapies that could improve survival outcomes. Citation Format: Sergio A. Vallejo Avila, Joel Michalek, Qianquian Liu, Adolfo E. Diaz Duque. Contemporary hospital-based study examining demographics, treatment patterns and survival outcomes of primary effusion lymphoma in the United States, with a specific emphasis on Hispanics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4857.
Year:
2024
Purpose: Glioblastoma (GBM) represents the most common primary brain tumor. Although anti-angiogenics are employed in the recurrent setting, they do not prolong survival. GBM is known to upregulate fatty acid synthase (FASN) to facilitate lipid biosynthesis. TVB-2640, a FASN inhibitor, impairs this activity. Patients and Methods: We conducted a prospective, single-center, open-label, unblinded, phase II study of TVB-2640 plus bevacizumab in patients with recurrent high-grade astrocytoma. Patients were randomized to TVB-2640 (100mg/m2 oral daily) plus bevacizumab (10mg/kg IV, D1 and D15) or bevacizumab monotherapy for cycle 1 only (28 days) for biomarker analysis. Thereafter, all patients received TVB-2640 plus bevacizumab until treatment-related toxicity or progressive disease. The primary endpoint was progression-free survival. Results: A total of 25 patients were enrolled. The most frequently reported AEs were palmar-plantar erythrodysesthesia, hypertension, mucositis, dry eye, fatigue and skin infection. Most were Grade 1 or 2 in intensity. The ORR for TVB-2640 plus bevacizumab was 56% (CR 17%, PR 39%). PFS6 for TVB-2640 plus bevacizumab was 31.4%. This represented a statistically significant improvement in PFS6 over historical bevacizumab monotherapy (BELOB 16%, p=0.008) and met the primary study endpoint. The observed OS6 was 68%, with survival not reaching significance by log rank test (p=0.56). Conclusions: In this phase II study of relapsed high-grade astrocytoma, TVB-2640 was found to be a well-tolerated oral drug that could be safely combined with bevacizumab. The favorable safety profile and response signals support the initiation of a larger multicenter trial of TVB-2640 plus bevacizumab in astrocytoma.
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (9)
Yidong Chen
Professor
University of Texas Health Science Center at San Antonio
Parth Anil Desai
Assistant Professor/Clinical Investigator
Fox Chase Cancer Center
Joel Michalek
Professor
University of Texas Health Science Center at San Antonio
Leon Bernal-Mizrachi
Professor and Chair
Wake Forest Baptist Medical Center
Carine Jaafar
University of Texas Health Science Center at San Antonio
Frank J Penedo
Professor
University of Miami
Michael Antoni
Professor
University of Miami
Matthew Butler
Associate Professor of Medicine
University of Texas at San Antonio
Patricia Chalela
Associate Professor
University of Texas Health Science Center at San Antonio
Make your next move.
Prepare your application
Review drafts before you send them.